var data={"title":"Postnatal care of hydrops fetalis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Postnatal care of hydrops fetalis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/contributors\" class=\"contributor contributor_credentials\">Michael E Speer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/contributors\" class=\"contributor contributor_credentials\">Leonard E Weisman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/contributors\" class=\"contributor contributor_credentials\">Melanie S Kim, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 29, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hydrops fetalis is a condition of excess fluid accumulation in the fetus that results in significant fetal demise and neonatal mortality. It was first described by Ballantyne in a case series of 65 human fetuses and newborn infants, in which he suggested there were a variety of etiologies [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/1\" class=\"abstract_t\">1</a>]. In 1943, Potter defined two forms of hydrops fetalis based upon etiology [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immune-mediated &minus; In immune-mediated cases, hydrops fetalis is a result of severe fetal anemia due to destruction of fetal red blood cells by maternal immunoglobulin G (IgG) antibodies. Before the introduction of antenatal Rh(D) (rhesus D antigen) <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> prophylaxis in the 1960s, the most frequent cause of hydrops fetalis was Rh incompatibility between the mother and fetus. (See <a href=\"topic.htm?path=postnatal-diagnosis-and-management-of-hemolytic-disease-of-the-fetus-and-newborn\" class=\"medical medical_review\">&quot;Postnatal diagnosis and management of hemolytic disease of the fetus and newborn&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonimmune &minus; Nonimmune hydrops fetalis (NHF) is associated with numerous disorders that include cardiac, pulmonary, infectious, and genetic etiologies (<a href=\"image.htm?imageKey=OBGYN%2F70066\" class=\"graphic graphic_table graphicRef70066 \">table 1</a>). NHF accounts for almost 90 percent of current hydropic cases in neonates.</p><p/><p>The postnatal care of hydrops fetalis will be reviewed here. The antenatal care of Rhesus alloimmunization and nonimmune hydrops fetalis is discussed separately. (See <a href=\"topic.htm?path=management-of-pregnancy-complicated-by-rhesus-d-alloimmunization\" class=\"medical medical_review\">&quot;Management of pregnancy complicated by Rhesus (D) alloimmunization&quot;</a> and <a href=\"topic.htm?path=nonimmune-hydrops-fetalis\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of hydrops fetalis is based upon antenatal ultrasonography or postnatal evaluation that demonstrates two or more of the following findings:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Skin edema</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pleural effusion</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pericardial effusion</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ascites</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polyhydramnios</p><p/><p>(See <a href=\"topic.htm?path=nonimmune-hydrops-fetalis#H7\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EPIDEMIOLOGY AND ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the implementation of antenatal Rh(D) <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> prophylaxis, the incidence of immune-mediated hydrops fetalis has drastically fallen from 80 percent of cases in 1970 to less than 10 percent in 2007 [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/3,4\" class=\"abstract_t\">3,4</a>]. The reported incidence of nonimmune hydrops fetalis (NHF) ranges from 1 in 1500 to 3800 births. The wide variation is based upon differences in population (eg, increased incidence of alpha thalassemia in Southeast Asia) and thoroughness of evaluation, and whether late pregnancy terminations were included in the analysis. (See <a href=\"topic.htm?path=nonimmune-hydrops-fetalis#H2\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;, section on 'Prevalence'</a>.)</p><p>In a review from a large national data set from the United States that identified 598 live-born infants with hydrops fetalis from a cohort of 253,651 infants discharged from a neonatal intensive care unit (NICU), the following were the most common conditions associated with hydrops fetalis [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Congenital heart problems (14 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heart rate abnormalities (10 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Twin-to-twin transfusions (9 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Noncardiac congenital anomalies (9 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chromosomal abnormalities (8 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Congenital viral infections (7 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Congenital anemia (5 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Congenital chylothorax (3 percent)</p><p/><p>A systematic review of the literature that identified over 1300 patients with non-immune hydrops fetalis classified etiologies into 14 classifications [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/5\" class=\"abstract_t\">5</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiovascular disease (20 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphatic dysplasia (15 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hematologic disease (9 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chromosomal abnormalities (9 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infections (7 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Syndromic causes without a known genetic defect (6 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Twin-to-twin transfusions and placental vascular abnormalities (4 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thoracic malformations (2 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inborn error of metabolism (1 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Congenital anomalies of the kidney and urinary tract (1 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thoracic tumors (1 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Miscellaneous (4 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic (20 percent)</p><p/><p>In an autopsy study of 429 neonates from a tertiary center in the United States, 32 cases (7 percent) had hydrops fetalis, of which 16 infants had cardiovascular disease and 6 had congenital infections [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/6\" class=\"abstract_t\">6</a>].</p><p>In Asia, the most common causes of hydrops fetalis are homozygous alpha-thalassemia and cardiac disease [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/7-9\" class=\"abstract_t\">7-9</a>].</p><p>The etiologies of NHF are discussed in greater detail separately (<a href=\"image.htm?imageKey=OBGYN%2F70066\" class=\"graphic graphic_table graphicRef70066 \">table 1</a>). (See <a href=\"topic.htm?path=nonimmune-hydrops-fetalis#H8\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;, section on 'Disorders associated with hydrops and antepartum management'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Understanding the basic mechanisms that underlie the development of hydrops fetalis is important in directing both antenatal and postnatal treatment of hydrops fetalis.</p><p>Normally, the formation of interstitial fluid from the vascular space is balanced by the return of interstitial fluid back to the central venous system through the lymphatic system. The process is governed by Starling's Law and is dependent upon the four following components:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Capillary hydrostatic pressure</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Capillary oncotic pressure</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interstitial hydrostatic pressure</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interstitial osmotic pressure, which is dependent on lymphatic return</p><p/><p>The fetus is particularly vulnerable to increased interstitial fluid accumulation because of its greater capillary permeability, compliant interstitial compartments, and increased susceptibility to impaired lymphatic flow.</p><p>In cases of hydrops fetalis, accumulation of interstitial fluid occurs because the production of interstitial fluid greatly exceeds the lymphatic return. Although the pathogenesis is not clearly understood, hydrops fetalis appears to be multifactorial due to mechanisms that produce elevated central venous pressure, impair lymphatic return, and increase capillary leakage.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Elevated venous pressure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Elevated central venous pressure (CVP) increases capillary hydrostatic pressure and impairs lymphatic return to the vascular space [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/10,11\" class=\"abstract_t\">10,11</a>].</p><p>Both low (eg, cardiac arrhythmia, congenital structural heart disease, and myocarditis) and high-output cardiac failure (eg, severe anemia, arterial-venous malformations, and twin-twin transfusion syndrome) cause elevated CVP that may result in hydrops fetalis [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4,12-20\" class=\"abstract_t\">4,12-20</a>]. Elevation of CVP appears to be a critical component in the pathogenesis of hydrops fetalis because animal studies have demonstrated that severe anemia alone does not cause hydrops fetalis, but rather only causes hydrops fetalis in the presence of increased CVP [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p>CVP elevation may also be caused by obstruction of either the superior <span class=\"nowrap\">and/or</span> inferior vena cavas as demonstrated in cases of congenital cystic adenomatoid malformation, omphalocele, cervical or mediastinal teratoma, or congenital high airway obstruction syndrome [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/23-27\" class=\"abstract_t\">23-27</a>]. Compression of the vascular system impedes lymphatic return and results in edema formation.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Impaired lymphatic drainage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lymph return to the central venous system is reduced either by structural abnormality or, as previously discussed, by functional impairment due to increased CVP.</p><p>Anomalous development results in structural dysgenesis of the lymphatic network and is seen in the following conditions: chylothorax, cervical hygroma, congenital lymphedema, and cystic lymphangiectasia [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4,28-31\" class=\"abstract_t\">4,28-31</a>]. These structural anomalies are often associated with chromosomal abnormalities, such as Turner syndrome [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"topic.htm?path=cystic-hygroma-and-increased-nuchal-translucency\" class=\"medical medical_review\">&quot;Cystic hygroma and increased nuchal translucency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Capillary oncotic pressure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In theory, reduced capillary oncotic pressure should contribute to hydrops fetalis. However, data from animal studies demonstrated that hypoproteinemia does not result in nonimmune hydrops fetalis (NHF) [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Hypoxia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Animal studies have shown that severe fetal hypoxia causes hydrops fetalis. In these studies, there is sustained activation of the renin-angiotensin system with elevation of renin in the absence of renal injury or elevation of CVP [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/34,35\" class=\"abstract_t\">34,35</a>]. In addition, hypoxia results in endothelial injury and interferes with nitric oxide and cyclic guanosine monophosphate production [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/36,37\" class=\"abstract_t\">36,37</a>], which may increase capillary leakage, resulting in greater movement of fluid from the vascular to the interstitial space.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In developed countries, most cases of hydrops fetalis will be diagnosed prior to delivery because of the routine use of antenatal ultrasound [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/38\" class=\"abstract_t\">38</a>]. Antenatal evaluation and management are discussed separately. (See <a href=\"topic.htm?path=nonimmune-hydrops-fetalis\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;</a>.)</p><p>The delivery of a fetus with hydrops fetalis requires close collaboration between the perinatologist and neonatologist. The care of a known affected case should take place at a tertiary center that can offer intrauterine intervention including prenatal exchange transfusion, expertise in neonatal resuscitation and pediatric surgery, and postnatal mechanical ventilatory support and exchange transfusion.</p><p>Postnatal management is divided into initial resuscitation directed towards stabilizing the cardiopulmonary status in the delivery room, assessment to identify the underlying cause, and if possible, directed therapy focused on treating the underlying cause.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Initial resuscitation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>At the time of delivery, hydrops fetalis increases the risk of birth trauma due to soft tissue dystocia, postpartum hemorrhage, and retained placenta. In utero aspiration of the pleural fluid or ascites prior to delivery may reduce the risk of dystocia and facilitate neonatal resuscitation. Cesarean birth should be reserved for routine obstetrical indications; however, the high frequency of nonreassuring fetal heart rate patterns and dystocia associated with hydrops fetalis increases the likelihood of cesarean delivery. (See <a href=\"topic.htm?path=nonimmune-hydrops-fetalis#H26\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;, section on 'Prognosis'</a>.)</p><p>Although prenatal ultrasound should provide guidance upon the level of resuscitation required, delivery room management should anticipate the needs of the most severely affected infant. Preparation should anticipate the need to drain fluid if there is significant ascites. Pleural effusions or pericardial effusions compromise ventilation or cardiac output, especially if the fluid has not been drained prior to delivery. If severe anemia is anticipated, unmatched type O, Rh(D) negative packed red blood cells should be available.</p><p>For initial neonatal resuscitation, we suggest using the guidelines jointly developed by the American Heart Association, American Academy of Pediatrics, and International Liaison Committee on Resuscitation that focus on the following three steps. (See <a href=\"topic.htm?path=neonatal-resuscitation-in-the-delivery-room\" class=\"medical medical_review\">&quot;Neonatal resuscitation in the delivery room&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial steps (provide warmth, position head, clear airway, dry, and stimulate)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Breathing (ventilation)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Circulation</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Breathing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most affected infants require endotracheal intubation because of respiratory depression. Intubation may be difficult because of edema of the head, neck, and oropharynx; thus, the most experienced available clinician should perform the procedure.</p><p>Drainage of pleural effusions and ascites by needle aspiration may be necessary, if adequate ventilation is not achieved after intubation. Paracentesis <span class=\"nowrap\">and/or</span> thoracentesis are performed using an 18- to 20-gauge angiocatheter attached to a three-way stopcock and syringe. After entry into the chest or abdominal cavity, the needle is removed and the plastic catheter remains in place to prevent damage to either the underlying lung or abdominal organs. Fluid is gently aspirated by syringe. In some cases, cardiocentesis may be required if there is evidence of cardiac tamponade.</p><p>Hydropic infants frequently require mechanical ventilatory support, even following drainage, as many will have pulmonary hypoplasia or respiratory distress syndrome [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/38\" class=\"abstract_t\">38</a>].</p><p>If the infant is born at or before 30 weeks gestation, prophylactic surfactant therapy is given. In older infants, rescue surfactant is considered if the arterial to alveolar oxygen ratio is less than 0.22 to 0.3. (See <a href=\"topic.htm?path=prevention-and-treatment-of-respiratory-distress-syndrome-in-preterm-infants\" class=\"medical medical_review\">&quot;Prevention and treatment of respiratory distress syndrome in preterm infants&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Circulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pallor, tachycardia, and tachypnea are findings suggestive of either cardiogenic shock or severe symptomatic anemia. Central venous lines are necessary for monitoring pressures and obtaining blood for testing, and if necessary, administration of fluids and medications, and for partial exchange transfusion. Catheterization of the umbilical vein provides quick central venous access.</p><p>Although most hydropic infants are normovolemic, fluid resuscitation may be required in infants near cardiovascular collapse. Inotropic support (eg, <a href=\"topic.htm?path=dopamine-pediatric-drug-information\" class=\"drug drug_pediatric\">dopamine</a>) may be required to improve cardiac output, especially in infants with low-output cardiac failure.</p><p>If known or suspected fetal anemia is suspected as the underlying cause of hydrops fetalis, a simple careful transfusion or an isovolemic partial exchange transfusion with packed group O, Rh(D) negative red blood cells should be performed. Isovolemic exchange is preferred, as these infants will have normal or increased vascular volume, and elevated central venous pressure [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/39\" class=\"abstract_t\">39</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Assessment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once the cardiopulmonary systems are stabilized, diagnostic evaluation is performed to determine the underlying cause of hydrops fetalis. Determining the etiology of the hydrops fetalis may direct further evaluation, guide treatment, and provide information for both the prognosis of the affected infant and genetic counseling for future pregnancies.</p><p>Assessment includes examination of the infant and the placenta, and diagnostic testing.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Examination of the infant and placenta</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The assessment begins with examination of the infant and the placenta.</p><p>Neonatal physical findings that are useful in directing the evaluation and management of the affected child include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Persistent cyanosis that is unresponsive to oxygen suggests the presence of structural heart disease or cardiac myopathy [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/15-18,40,41\" class=\"abstract_t\">15-18,40,41</a>]. (See <a href=\"topic.htm?path=diagnosis-and-initial-management-of-cyanotic-heart-disease-in-the-newborn\" class=\"medical medical_review\">&quot;Diagnosis and initial management of cyanotic heart disease in the newborn&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evidence of dermal hematopoiesis and hepatomegaly, with or without splenomegaly, is suggestive of intrauterine congenital viral infections (eg, cytomegalovirus and rubella) [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/42,43\" class=\"abstract_t\">42,43</a>]. (See <a href=\"topic.htm?path=overview-of-torch-infections\" class=\"medical medical_review\">&quot;Overview of TORCH infections&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypotonia may be seen in hydropic infants with congenital myopathy [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/44-46\" class=\"abstract_t\">44-46</a>] or inherited error of metabolism including storage diseases, such as Gaucher disease [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/47-49\" class=\"abstract_t\">47-49</a>]. In addition, cases of congenital hypothyroidism, which is associated with hypotonia, have been reported in hydropic infants [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/50,51\" class=\"abstract_t\">50,51</a>]. (See <a href=\"topic.htm?path=congenital-myopathies\" class=\"medical medical_review\">&quot;Congenital myopathies&quot;</a> and <a href=\"topic.htm?path=gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition to hypotonia, other clinical features of metabolic storage diseases may include hepatomegaly, facial dysmorphism, and cardiomyopathy [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/52-56\" class=\"abstract_t\">52-56</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Findings suggestive of a chromosomal abnormality may be present, such as congenital lymphedema of the hands and feet, webbed neck, nail dysplasia, high palate, and short fourth metacarpal, as seen in infants with Turner syndrome. Other chromosomal abnormalities associated with hydrops fetalis include Trisomies 21, 18, and 12, and triploidy [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-turner-syndrome\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Turner syndrome&quot;</a> and <a href=\"topic.htm?path=down-syndrome-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Down syndrome: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=congenital-cytogenetic-abnormalities\" class=\"medical medical_review\">&quot;Congenital cytogenetic abnormalities&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other anomalies associated with hydrops fetalis, such as omphalocele and intrathoracic masses, may be detected on physical examination.</p><p/><p>The placenta should be examined for evidence of chorioangioma [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/57\" class=\"abstract_t\">57</a>], congenital infection [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/58\" class=\"abstract_t\">58</a>], and, in the case of twin pregnancies, twin-to-twin transfusion [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/19,20\" class=\"abstract_t\">19,20</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Diagnostic evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial studies include blood gas measurements, complete blood count, and, if anemia is suspected, type and cross match.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blood gas measurements provide information on the infant's cardiopulmonary status and guide further interventions.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count includes the hematocrit, which can assess whether anemia is present, and if so, the severity of anemia. Examination of the blood smear can determine whether there is an ongoing hemolytic process and may provide clues to the diagnosis of the underlying cause.</p><p/><p>Further diagnostic studies include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiac evaluation &minus; In hydropic infants suspected to have cardiac abnormalities (<a href=\"image.htm?imageKey=OBGYN%2F77350\" class=\"graphic graphic_table graphicRef77350 \">table 2</a>), we perform an electrocardiogram to detect arrhythmias and echocardiogram to detect cardiac structural and functional abnormalities.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thoracic and abdominal evaluation &minus; Radiographs are useful to ascertain the presence and size of pleural effusions, and as a screen for potential mass lesions, and pulmonary or cardiac disease. If there is a suspicion for an intrathoracic or abdominal abnormality, other imaging modalities, such as computerized tomography, ultrasonography, or magnetic resonance imaging provide better resolution to identify the abnormality (eg, cystic adenomatoid malformation [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4,26\" class=\"abstract_t\">4,26</a>], leiomyosarcoma [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/24\" class=\"abstract_t\">24</a>], or pulmonary sequestration [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/59\" class=\"abstract_t\">59</a>]) (<a href=\"image.htm?imageKey=OBGYN%2F66844\" class=\"graphic graphic_table graphicRef66844 \">table 3</a>). Identification of surgically correctable lesions is important as there are case reports of improved outcome with surgical intervention [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/24,60\" class=\"abstract_t\">24,60</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluation for infection &minus; Both congenital bacterial and viral infections are associated with cases of hydrops fetalis (<a href=\"image.htm?imageKey=OBGYN%2F72575\" class=\"graphic graphic_table graphicRef72575 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4,61\" class=\"abstract_t\">4,61</a>]. Intrauterine infection of the fetus may arise from pathogens that ascend from the vagina and cervix, or are transferred from the maternal circulation through the uteroplacental circulation. Individual infections have characteristic histopathologic findings within the placenta. Thus, placental examination by a pathologist should be performed when infection is considered as a causal or contributing factor for hydrops fetalis.</p><p/><p class=\"bulletIndent1\">Congenital viral infections are the most common infectious agents associated with hydrops fetalis [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4\" class=\"abstract_t\">4</a>]. Currently, diagnostic testing for congenital viral infections includes serologic testing and cultures of different body fluids, and molecular techniques, such as polymerase chain reaction. The choice of tests depends upon the organism. (See <a href=\"topic.htm?path=overview-of-torch-infections#H609355024\" class=\"medical medical_review\">&quot;Overview of TORCH infections&quot;, section on 'Approach to the infant with suspected intrauterine infection'</a>.)</p><p/><p class=\"bulletIndent1\">Hydrops fetalis associated with cytomegalovirus (CMV) [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4,6\" class=\"abstract_t\">4,6</a>], parvovirus [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4,6\" class=\"abstract_t\">4,6</a>], syphilis [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/58,62,63\" class=\"abstract_t\">58,62,63</a>], and toxoplasmosis [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/64\" class=\"abstract_t\">64</a>] is generally due to anemia and the resultant high-output cardiac failure. There are also cases of hydrops fetalis due to myocarditis from CMV [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/65\" class=\"abstract_t\">65</a>], parvovirus [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/6\" class=\"abstract_t\">6</a>], and coxsackie virus [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/66\" class=\"abstract_t\">66</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluation of anemia &minus; As discussed previously, prompt intervention with transfusion should be performed in infants with severe symptomatic anemia. Once the cardiopulmonary status of the infant is stabilized, the cause of anemia should be determined or confirmed if there was a predetermined antenatal cause. Anemia can be due to hemolysis, such as isoimmune hemolytic anemia or inherited disorders of red blood cells (eg, homozygous alpha thalassemia or hereditary spherocytosis), blood loss from fetal to maternal hemorrhage [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/67,68\" class=\"abstract_t\">67,68</a>], or reduced fetal red blood cell production (eg, parvovirus B12 infection) (<a href=\"image.htm?imageKey=OBGYN%2F62279\" class=\"graphic graphic_table graphicRef62279 \">table 5</a>). An unusual form of anemia (transient abnormal myelopoiesis or transient leukemia) is found in 10 percent of newborn infants with Trisomy 21. (See <a href=\"topic.htm?path=pathophysiology-of-alpha-thalassemia#H25\" class=\"medical medical_review\">&quot;Pathophysiology of alpha thalassemia&quot;, section on 'Hydrops fetalis and hemoglobin Bart's'</a> and <a href=\"topic.htm?path=overview-of-hemolytic-anemias-in-children\" class=\"medical medical_review\">&quot;Overview of hemolytic anemias in children&quot;</a> and <a href=\"topic.htm?path=down-syndrome-clinical-features-and-diagnosis#H15\" class=\"medical medical_review\">&quot;Down syndrome: Clinical features and diagnosis&quot;, section on 'Transient myeloproliferative disorder'</a>.)</p><p/><p class=\"bulletIndent1\">Examination of the blood smear will determine whether hemolysis is the cause of anemia. If hemolysis is present, further testing includes the infant's blood type, Coombs test, and tests to identify inherited red blood cell disorders. (See <a href=\"topic.htm?path=overview-of-hemolytic-anemias-in-children\" class=\"medical medical_review\">&quot;Overview of hemolytic anemias in children&quot;</a>.)</p><p/><p class=\"bulletIndent1\">If fetal maternal hemorrhage is suspected, Kleihauer-Betke test, which measures the percentage of fetal red blood in the maternal blood by flow cytometry, can be used to support the diagnosis. (See <a href=\"topic.htm?path=prevention-of-rhesus-d-alloimmunization-in-pregnancy#H3794159706\" class=\"medical medical_review\">&quot;Prevention of Rhesus (D) alloimmunization in pregnancy&quot;, section on 'Testing for fetomaternal hemorrhage'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chromosomal microarray analysis &minus; Chromosomal microarray analysis (CMA) is an array-based molecular cytogenic method of testing for a genetic disorder. Like the conventional prenatal genetic test known as Giemsa(G)-banding of metaphase chromosomes or karyotyping, CMA is now recommended as the first-line genetic test in pregnancies and in infants showing <a href=\"http://www.acog.org/Patients/FAQs/Screening-Tests-for-Birth-Defects&amp;token=ZBfn8l++xe4OdasARKyfw8JeonQVfpjicp9SEqMnUFkrAy7eDCG0A792J+JSYSZ0csknD9lq25qEDgRmDTefV7ig2GeovFIdc/mhNku7Nfk=&amp;TOPIC_ID=5027\" target=\"_blank\" class=\"external\">abnormalities</a> on an ultrasound screen or by physical examination. CMA can identify major chromosomal defects such as Down syndrome, as can karyotyping, but it is associated with a higher diagnostic yield and faster turnaround time. CMA can be performed in samples that are obtained through amniocentesis, chorionic villus, or fetal blood sampling. Antenatal CMA provides useful information when reviewing antenatal management options with the parents, such as termination of the pregnancy or invasive therapeutic interventions. (See <a href=\"topic.htm?path=nonimmune-hydrops-fetalis#H600831234\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;, section on 'Postdiagnostic evaluation'</a> and <a href=\"topic.htm?path=use-of-chromosomal-microarray-in-obstetrics\" class=\"medical medical_review\">&quot;Use of chromosomal microarray in obstetrics&quot;</a>.)</p><p/><p class=\"bulletIndent1\">If fetal CMA has not been performed, then CMA should be performed regardless of the outcome of the infant because hydrops fetalis is associated with an increased risk of a chromosomal abnormality, including metabolic storage disease and mutations associated with cardiac disease [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/55,69-73\" class=\"abstract_t\">55,69-73</a>]. Genetic counseling should be provided to parents if a chromosomal abnormality is detected to direct the management of future pregnancies.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluation for inborn errors of metabolic disease &minus; Metabolic disorders result from the absence or abnormality of an enzyme or its cofactor, leading to either accumulation or deficiency of a specific metabolite (<a href=\"image.htm?imageKey=PEDS%2F57407\" class=\"graphic graphic_table graphicRef57407 \">table 6</a>) [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/52-56,74-76\" class=\"abstract_t\">52-56,74-76</a>]. The outcome for <span class=\"nowrap\">infants/fetuses</span> with hydrops fetalis and an inborn error of metabolic disease is poor. In addition, the recurrence rate for future pregnancies is high, as most of these diseases are due to an inherited genetic defect. As a result, the diagnosis is important for future family planning [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/73\" class=\"abstract_t\">73</a>]. The evaluation of inborn errors of metabolism is discussed separately. (See <a href=\"topic.htm?path=inborn-errors-of-metabolism-metabolic-emergencies\" class=\"medical medical_review\">&quot;Inborn errors of metabolism: Metabolic emergencies&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rare causes &minus; A rare inheritable condition to consider is familial hemophagocytic lymphohistiocytosis due to mutation in the gene that encodes for Munc13-4 [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/77\" class=\"abstract_t\">77</a>].</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Further management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted previously, mechanical ventilation is often required because of lung hypoplasia. In addition, continued drainage of persistent pleural effusions and ascites may be needed.</p><p>Additional management is directed towards the underlying cause of hydrops fetalis and includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Correction of anemia and treatment of hyperbilirubinemia (see <a href=\"topic.htm?path=postnatal-diagnosis-and-management-of-hemolytic-disease-of-the-fetus-and-newborn\" class=\"medical medical_review\">&quot;Postnatal diagnosis and management of hemolytic disease of the fetus and newborn&quot;</a> and <a href=\"topic.htm?path=treatment-of-unconjugated-hyperbilirubinemia-in-term-and-late-preterm-infants\" class=\"medical medical_review\">&quot;Treatment of unconjugated hyperbilirubinemia in term and late preterm infants&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Correction of cardiac arrhythmias with cardioversion, medication, or pacing</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgical excision of resectable masses [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/24\" class=\"abstract_t\">24</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Administration of appropriate antimicrobial agents in infants with infections</p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">OUTCOME</span></p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Mortality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Despite intensive prenatal and postnatal interventions, live-born infants with hydrops fetalis have a 50 percent mortality rate [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4,7,38,78-80\" class=\"abstract_t\">4,7,38,78-80</a>]. Mortality rate is dependent upon the underlying cause of hydrops fetalis.</p><p>In the previously mentioned review of 598 live-born infants with hydrops fetalis, the mortality rate was highest in infants with congenital anomalies (58 percent) and lowest in infants with isolated congenital chylothorax (6 percent) [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4\" class=\"abstract_t\">4</a>]. In a logistic regression analysis, risk factors associated with decreased survival included lower gestational age, five minute Apgar score of 3 or less, and need for greater supportive care defined by high concentration of inspired oxygen and high-frequency ventilatory support.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Neurodevelopment outcome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In survivors of hydrops fetalis, poor neurodevelopment outcome appears to be the most significant morbidity. This was illustrated in the following case series:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one case series, 19 of 51 live-born infants with hydrops fetalis survived beyond one year of life [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/81\" class=\"abstract_t\">81</a>]. At one year follow-up, 13 patients had normal development, two had mild developmental delay, one had intellectual disability (mental retardation), and three had severe psychomotor retardation, of which two were very low birth weight infants (birth weight less than 1500 g).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study of 11 infants with hydrops fetalis due to fetal tachycardia, of which 10 received intrauterine treatment, neonatal cranial ultrasonography demonstrated periventricular echogenicity in three patients (including one patient with a pseudocyst), and porencephalic cyst suggestive of an antenatal parenchymal hemorrhage in another patient [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/82\" class=\"abstract_t\">82</a>]. The other seven infants had normal studies. Ten patients were discharged from the neonatal intensive care unit (NICU) and were assessed for cognitive and neurologic function between 6 months and 12 years of age. Eight patients had normal neurologic and cognitive function, one patient had mild hemiplegia with normal cognitive ability, and one had cognitive developmental delay.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prognosis is generally poor in patients with twin-twin transfusion because they are frequently delivered prior to 30 weeks gestation. In one case series of 25 pregnancies with twin-twin transfusion, hydrops fetalis presented in 10 cases [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/20\" class=\"abstract_t\">20</a>]. Two-thirds of hydropic infants died and, of the survivors, half had cerebral palsy.</p><p/><p>Because of the findings in these studies, neurodevelopmental evaluation should be provided to all survivors of hydrops fetalis [<a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/78\" class=\"abstract_t\">78</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Recurrence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of recurrence depends upon the underlying etiology. The recurrence rate is greatest in families with infants who have a chromosomal abnormality. Therefore, every effort should be made to determine the cause of hydrops including autopsies and chromosomal microarray analysis (CMA) of non-surviving infants and non-viable fetuses.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hydrops fetalis is defined as the presence of two or more of the following fetal findings: skin edema, pleural effusion, pericardial effusion, ascites, and polyhydramnios. It may be caused by immune or nonimmune-mediated processes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With the widespread use of antenatal Rh(D) <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> prophylaxis, nonimmune causes account for 90 percent of the cases of hydrops fetalis. The causes of nonimmune hydrops fetalis are heterogeneous and include cardiac, pulmonary, metabolic, hematologic, and infectious etiologies (<a href=\"image.htm?imageKey=OBGYN%2F70066\" class=\"graphic graphic_table graphicRef70066 \">table 1</a>). (See <a href=\"topic.htm?path=nonimmune-hydrops-fetalis#H8\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;, section on 'Disorders associated with hydrops and antepartum management'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although the pathogenesis is not clearly understood, hydrops fetalis appears to be multifactorial due to mechanisms that produce elevated central venous pressure, impair lymphatic return, and increase capillary leakage. (See <a href=\"#H4\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In developed countries, with the routine use of antenatal ultrasound, most cases of hydrops fetalis will be diagnosed prior to delivery. Intrauterine evaluation and management provided at a tertiary center may improve perinatal outcome. (See <a href=\"topic.htm?path=nonimmune-hydrops-fetalis\" class=\"medical medical_review\">&quot;Nonimmune hydrops fetalis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The delivery of a fetus with hydrops fetalis requires close collaboration between the perinatologist and neonatologist. We suggest that delivery should be at a tertiary center with expertise in neonatal resuscitation, pediatric surgery, exchange transfusion, and mechanical ventilation (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postnatal management is divided into initial resuscitation, assessment to identify the underlying cause, and treatment of the underlying cause, if possible. (See <a href=\"#H9\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial resuscitation is directed towards stabilizing the cardiopulmonary status of the infant. We suggest following guidelines jointly developed by the American Heart Association, American Academy of Pediatrics, and International Liaison Committee on Resuscitation for initial neonatal resuscitation (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"topic.htm?path=neonatal-resuscitation-in-the-delivery-room\" class=\"medical medical_review\">&quot;Neonatal resuscitation in the delivery room&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition, delivery room management includes preparation to drain fluid if significant ascites <span class=\"nowrap\">and/or</span> pleural effusions compromise ventilation, and the availability of unmatched type O, Rh(D) negative packed red blood cells for transfusion in cases of severe anemia. (See <a href=\"#H10\" class=\"local\">'Initial resuscitation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Once the cardiopulmonary system of the infant is stabilized, diagnostic evaluation is performed to determine the underlying cause of hydrops fetalis. Determining the etiology of the hydrops fetalis may direct further evaluation, guide treatment, and provide information on prognosis of the affected infant and genetic counseling for future pregnancies. (See <a href=\"#H13\" class=\"local\">'Assessment'</a> above and <a href=\"#H16\" class=\"local\">'Further management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mortality rate for live-born infants with hydrops fetalis is approximately 50 percent and varies depending on the underlying cause of hydrops fetalis. (See <a href=\"#H17\" class=\"local\">'Outcome'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Ballantyne JW. The diseases and deformities of the foetus: An attempt towards a new system of ante-natal pathology, Oliver &amp; Boyd, Edinburgh 1892.</li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/2\" class=\"nounderline abstract_t\">Potter EL. Universal edema of the fetus unassociated with erythroblastosis. Am J Obstet Gynecol 1943; 46:130.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/3\" class=\"nounderline abstract_t\">Macafee CA, Fortune DW, Beischer NA. Non-immunological hydrops fetalis. J Obstet Gynaecol Br Commonw 1970; 77:226.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/4\" class=\"nounderline abstract_t\">Abrams ME, Meredith KS, Kinnard P, Clark RH. Hydrops fetalis: a retrospective review of cases reported to a large national database and identification of risk factors associated with death. Pediatrics 2007; 120:84.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/5\" class=\"nounderline abstract_t\">Bellini C, Donarini G, Paladini D, et al. Etiology of non-immune hydrops fetalis: An update. Am J Med Genet A 2015; 167A:1082.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/6\" class=\"nounderline abstract_t\">Rodr&iacute;guez MM, Bruce JH, Jim&eacute;nez XF, et al. Nonimmune hydrops fetalis in the liveborn: series of 32 autopsies. Pediatr Dev Pathol 2005; 8:369.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/7\" class=\"nounderline abstract_t\">Yang YH, Teng RJ, Tang JR, et al. Etiology and outcome of hydrops fetalis. J Formos Med Assoc 1998; 97:16.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/8\" class=\"nounderline abstract_t\">Liao C, Wei J, Li Q, et al. Nonimmune hydrops fetalis diagnosed during the second half of pregnancy in Southern China. Fetal Diagn Ther 2007; 22:302.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/9\" class=\"nounderline abstract_t\">Huang HR, Tsay PK, Chiang MC, et al. Prognostic factors and clinical features in liveborn neonates with hydrops fetalis. Am J Perinatol 2007; 24:33.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/10\" class=\"nounderline abstract_t\">Gest AL, Bair DK, Vander Straten MC. The effect of outflow pressure upon thoracic duct lymph flow rate in fetal sheep. Pediatr Res 1992; 32:585.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/11\" class=\"nounderline abstract_t\">Gest AL, Bair DK, Vander Straten MC. Thoracic duct lymph flow in fetal sheep with increased venous pressure from electrically induced tachycardia. Biol Neonate 1993; 64:325.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/12\" class=\"nounderline abstract_t\">Kanzaki T, Chiba Y. Evaluation of the preload condition of the fetus by inferior vena caval blood flow pattern. Fetal Diagn Ther 1990; 5:168.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/13\" class=\"nounderline abstract_t\">Weiner CP. Umbilical pressure measurement in the evaluation of nonimmune hydrops fetalis. Am J Obstet Gynecol 1993; 168:817.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/14\" class=\"nounderline abstract_t\">Chiba Y, Kobayashi H, Kanzaki T, Murakami M. Quantitative analysis of cardiac function in non-immunological hydrops fetalis. Fetal Diagn Ther 1990; 5:175.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/15\" class=\"nounderline abstract_t\">Knilans TK. Cardiac abnormalities associated with hydrops fetalis. Semin Perinatol 1995; 19:483.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/16\" class=\"nounderline abstract_t\">Henrich W, Fuchs I, B&uuml;hrer C, et al. Isolated cardiomegaly in the second trimester as an early sign of fetal hydrops due to intracranial arteriovenous malformation. J Clin Ultrasound 2003; 31:445.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/17\" class=\"nounderline abstract_t\">Jaeggi ET, Hornberger LK, Smallhorn JF, Fouron JC. Prenatal diagnosis of complete atrioventricular block associated with structural heart disease: combined experience of two tertiary care centers and review of the literature. Ultrasound Obstet Gynecol 2005; 26:16.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/18\" class=\"nounderline abstract_t\">Simpson JM, Sharland GK. Fetal tachycardias: management and outcome of 127 consecutive cases. Heart 1998; 79:576.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/19\" class=\"nounderline abstract_t\">Hayakawa M, Oshiro M, Mimura S, et al. Twin-to-twin transfusion syndrome with hydrops: a retrospective analysis of ten cases. Am J Perinatol 1999; 16:263.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/20\" class=\"nounderline abstract_t\">Matsuda Y, Kouno S. Fetal and neonatal outcomes in twin oligohydramnios-polyhydramnios sequence including cerebral palsy. Fetal Diagn Ther 2002; 17:268.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/21\" class=\"nounderline abstract_t\">Blair DK, Vander Straten MC, Gest AL. Hydrops in fetal sheep from rapid induction of anemia. Pediatr Res 1994; 35:560.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/22\" class=\"nounderline abstract_t\">Moise KJ Jr, Carpenter RJ Jr, Hesketh DE. Do abnormal Starling forces cause fetal hydrops in red blood cell alloimmunization? Am J Obstet Gynecol 1992; 167:907.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/23\" class=\"nounderline abstract_t\">Ierullo AM, Ganapathy R, Crowley S, et al. Neonatal outcome of antenatally diagnosed congenital cystic adenomatoid malformations. Ultrasound Obstet Gynecol 2005; 26:150.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/24\" class=\"nounderline abstract_t\">Golladay ES, Mollitt DL. Surgically correctable fetal hydrops. J Pediatr Surg 1984; 19:59.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/25\" class=\"nounderline abstract_t\">Lim FY, Crombleholme TM, Hedrick HL, et al. Congenital high airway obstruction syndrome: natural history and management. J Pediatr Surg 2003; 38:940.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/26\" class=\"nounderline abstract_t\">Rice HE, Estes JM, Hedrick MH, et al. Congenital cystic adenomatoid malformation: a sheep model of fetal hydrops. J Pediatr Surg 1994; 29:692.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/27\" class=\"nounderline abstract_t\">Wesolowski A, Piazza A. A case of mediastinal teratoma as a cause of nonimmune hydrops fetalis, and literature review. Am J Perinatol 2008; 25:507.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/28\" class=\"nounderline abstract_t\">Tanriverdi HA, Ertan AK, Hendrik HJ, et al. Outcome of cystic hygroma in fetuses with normal karyotypes depends on associated findings. Eur J Obstet Gynecol Reprod Biol 2005; 118:40.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/29\" class=\"nounderline abstract_t\">Bellini C, Mazzella M, Arioni C, et al. Hennekam syndrome presenting as nonimmune hydrops fetalis, congenital chylothorax, and congenital pulmonary lymphangiectasia. Am J Med Genet A 2003; 120A:92.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/30\" class=\"nounderline abstract_t\">Daniel-Spiegel E, Ghalamkarpour A, Spiegel R, et al. Hydrops fetalis: an unusual prenatal presentation of hereditary congenital lymphedema. Prenat Diagn 2005; 25:1015.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/31\" class=\"nounderline abstract_t\">Bellini C, Hennekam RC, Boccardo F, et al. Nonimmune idiopathic hydrops fetalis and congenital lymphatic dysplasia. Am J Med Genet A 2006; 140:678.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/32\" class=\"nounderline abstract_t\">Basgul A, G&uuml;d&uuml;c&uuml; N, Kavak ZN, et al. Three fetuses karyotyped as Turner syndrome with cystic hygroma developing hydrops: prognosis and outcome. Clin Exp Obstet Gynecol 2007; 34:182.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/33\" class=\"nounderline abstract_t\">Mo&iuml;se AA, Gest AL, Weickmann PH, McMicken HW. Reduction in plasma protein does not affect body water content in fetal sheep. Pediatr Res 1991; 29:623.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/34\" class=\"nounderline abstract_t\">O'Connell AE, Boyce AC, Lumbers ER, Gibson KJ. The effects of asphyxia on renal function in fetal sheep at midgestation. J Physiol 2003; 552:933.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/35\" class=\"nounderline abstract_t\">Lumbers ER, Gunn AJ, Zhang DY, et al. Nonimmune hydrops fetalis and activation of the renin-angiotensin system after asphyxia in preterm fetal sheep. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1045.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/36\" class=\"nounderline abstract_t\">De Groot CJ, Oepkes D, Egberts J, Kanhai HH. Evidence of endothelium involvement in the pathophysiology of hydrops fetalis? Early Hum Dev 2000; 57:205.</a></li><li class=\"breakAll\">Gidday JM, Park TS, Shah AR, Gonzales ER. Modulation of basal and postischemic leukocyte-endothelial adherence by nitric oxide. Stroke 1998; 29:1423; discussion 1429-30.</li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/38\" class=\"nounderline abstract_t\">Wafelman LS, Pollock BH, Kreutzer J, et al. Nonimmune hydrops fetalis: fetal and neonatal outcome during 1983-1992. Biol Neonate 1999; 75:73.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/39\" class=\"nounderline abstract_t\">Phibbs RH, Johnson P, Tooley WH. Cardiorespiratory status of erythroblastotic newborn infants. II. Blood volume, hematocrit, and serum albumin concentration in relation to hydrops fetalis. Pediatrics 1974; 53:13.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/40\" class=\"nounderline abstract_t\">Kothari DS, Skinner JR. Neonatal tachycardias: an update. Arch Dis Child Fetal Neonatal Ed 2006; 91:F136.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/41\" class=\"nounderline abstract_t\">Tanel RE, Rhodes LA. Fetal and neonatal arrhythmias. Clin Perinatol 2001; 28:187.</a></li><li class=\"breakAll\">Rudolph AJ. Thorax, Abdomen, Blood, Endocrine and Metabolic Disorders. In: Atlas of the Newborn, BC Decker Inc, Hamilton, Canada 1997. Vol 5, p.197.</li><li class=\"breakAll\">Rudolph AJ. Dermatology and Perinatal Infection. In: Atlas of the Newborn, BC Decker Inc, Hamilton, Canada 1997. Vol 4, p.118,127.</li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/44\" class=\"nounderline abstract_t\">Afifi AM, Bhatia AR, Eyal F. Hydrops fetalis associated with congenital myotonic dystrophy. Am J Obstet Gynecol 1992; 166:929.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/45\" class=\"nounderline abstract_t\">Dufour P, Berard J, Vinatier D, et al. Myotonic dystrophy and pregnancy. A report of two cases and a review of the literature. Eur J Obstet Gynecol Reprod Biol 1997; 72:159.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/46\" class=\"nounderline abstract_t\">Vardon D, Chau C, Sigodi S, et al. Congenital rapidly fatal form of nemaline myopathy with fetal hydrops and arthrogryposis. A case report and review. Fetal Diagn Ther 1998; 13:244.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/47\" class=\"nounderline abstract_t\">Steenhout P, Elmer C, Clercx A, et al. Carnitine deficiency with cardiomyopathy presenting as neonatal hydrops: successful response to carnitine therapy. J Inherit Metab Dis 1990; 13:69.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/48\" class=\"nounderline abstract_t\">Lazebnik N, Lazebnik RS. The prenatal presentation of congenital erythropoietic porphyria: report of two siblings with elevated maternal serum alpha-fetoprotein. Prenat Diagn 2004; 24:282.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/49\" class=\"nounderline abstract_t\">Kassem E, Dolfin T, Litmanowitz I, et al. Familial perinatal hemochromatosis: a disease that causes recurrent non-immune hydrops. J Perinat Med 1999; 27:122.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/50\" class=\"nounderline abstract_t\">Watson WJ, Fiegen MM. Fetal thyrotoxicosis associated with nonimmune hydrops. Am J Obstet Gynecol 1995; 172:1039.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/51\" class=\"nounderline abstract_t\">Kessel I, Makhoul IR, Sujov P. Congenital hypothyroidism and nonimmune hydrops fetalis: associated? Pediatrics 1999; 103:E9.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/52\" class=\"nounderline abstract_t\">Lemyre E, Russo P, Melan&ccedil;on SB, et al. Clinical spectrum of infantile free sialic acid storage disease. Am J Med Genet 1999; 82:385.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/53\" class=\"nounderline abstract_t\">Mignot C, Gelot A, Bessi&egrave;res B, et al. Perinatal-lethal Gaucher disease. Am J Med Genet A 2003; 120A:338.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/54\" class=\"nounderline abstract_t\">Wraith JE. Lysosomal disorders. Semin Neonatol 2002; 7:75.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/55\" class=\"nounderline abstract_t\">Pattison S, Pankarican M, Rupar CA, et al. Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression. Hum Mutat 2004; 23:32.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/56\" class=\"nounderline abstract_t\">Staretz-Chacham O, Lang TC, LaMarca ME, et al. Lysosomal storage disorders in the newborn. Pediatrics 2009; 123:1191.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/57\" class=\"nounderline abstract_t\">Russell RT, Carlin A, Ashworth M, Welch CR. Diffuse placental chorioangiomatosis and fetal hydrops. Fetal Diagn Ther 2007; 22:183.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/58\" class=\"nounderline abstract_t\">Barton JR, Thorpe EM Jr, Shaver DC, et al. Nonimmune hydrops fetalis associated with maternal infection with syphilis. Am J Obstet Gynecol 1992; 167:56.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/59\" class=\"nounderline abstract_t\">da Silva OP, Ramanan R, Romano W, et al. Nonimmune hydrops fetalis, pulmonary sequestration, and favorable neonatal outcome. Obstet Gynecol 1996; 88:681.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/60\" class=\"nounderline abstract_t\">Mitanchez D, Gr&eacute;bille AG, Parat S, et al. Delayed surgery in pericardial teratoma with neonatal hydrops. Eur J Pediatr Surg 2005; 15:431.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/61\" class=\"nounderline abstract_t\">Barron SD, Pass RF. Infectious causes of hydrops fetalis. Semin Perinatol 1995; 19:493.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/62\" class=\"nounderline abstract_t\">Berkowitz K, Baxi L, Fox HE. False-negative syphilis screening: the prozone phenomenon, nonimmune hydrops, and diagnosis of syphilis during pregnancy. Am J Obstet Gynecol 1990; 163:975.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/63\" class=\"nounderline abstract_t\">Chawla V, Pandit PB, Nkrumah FK. Congenital syphilis in the newborn. Arch Dis Child 1988; 63:1393.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/64\" class=\"nounderline abstract_t\">Zornes SL, Anderson PG, Lott RL. Congenital toxoplasmosis in an infant with hydrops fetalis. South Med J 1988; 81:391.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/65\" class=\"nounderline abstract_t\">Sampath V, Narendran V, Donovan EF, et al. Nonimmune hydrops fetalis and fulminant fatal disease due to congenital cytomegalovirus infection in a premature infant. J Perinatol 2005; 25:608.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/66\" class=\"nounderline abstract_t\">Bates HR Jr. Coxsackie virus B3 calcific pancarditis and hydrops fetalis. Am J Obstet Gynecol 1970; 106:629.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/67\" class=\"nounderline abstract_t\">Lau MS, Tan JV, Tan TY, et al. Idiopathic chronic fetomaternal haemorrhage resulting in hydrops--a case report. Ann Acad Med Singapore 2003; 32:642.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/68\" class=\"nounderline abstract_t\">Giacoia GP. Severe fetomaternal hemorrhage: a review. Obstet Gynecol Surv 1997; 52:372.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/69\" class=\"nounderline abstract_t\">Allan LD, Sharland GK, Chita SK, et al. Chromosomal anomalies in fetal congenital heart disease. Ultrasound Obstet Gynecol 1991; 1:8.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/70\" class=\"nounderline abstract_t\">Nadel A, Bromley B, Benacerraf BR. Nuchal thickening or cystic hygromas in first- and early second-trimester fetuses: prognosis and outcome. Obstet Gynecol 1993; 82:43.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/71\" class=\"nounderline abstract_t\">Landrum BG, Johnson DE, Ferrara B, et al. Hydrops fetalis and chromosomal trisomies. Am J Obstet Gynecol 1986; 154:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/72\" class=\"nounderline abstract_t\">Hempel M, Casar Tena T, Diehl T, et al. Compound heterozygous GATA5 mutations in a girl with hydrops fetalis, congenital heart defects and genital anomalies. Hum Genet 2017; 136:339.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/73\" class=\"nounderline abstract_t\">Haverkamp F, Jacobs D, Cantz M, et al. Nonimmune hydrops fetalis with galactosialidosis: consequences for family planning. Fetal Diagn Ther 1996; 11:114.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/74\" class=\"nounderline abstract_t\">Claeys M, Van der Hoeven M, de Die-Smulders C, et al. Early-infantile type of galactosialidosis as a cause of heart failure and neonatal ascites. J Inherit Metab Dis 1999; 22:666.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/75\" class=\"nounderline abstract_t\">Chab&aacute;s A, Gort L, D&iacute;az-Font A, et al. Perinatal lethal phenotype with generalized ichthyosis in a type 2 Gaucher disease patient with the [L444P;E326K]/P182L genotype: effect of the E326K change in neonatal and classic forms of the disease. Blood Cells Mol Dis 2005; 35:253.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/76\" class=\"nounderline abstract_t\">Colmant C, Picone O, Froissart R, et al. Second-trimester diagnosis of mucopolysaccharidosis type IV a presenting as hydrops fetalis. Prenat Diagn 2006; 26:750.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/77\" class=\"nounderline abstract_t\">Bechara E, Dijoud F, de Saint Basile G, et al. Hemophagocytic lymphohistiocytosis with Munc13-4 mutation: a cause of recurrent fatal hydrops fetalis. Pediatrics 2011; 128:e251.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/78\" class=\"nounderline abstract_t\">Wy CA, Sajous CH, Loberiza F, Weiss MG. Outcome of infants with a diagnosis of hydrops fetalis in the 1990s. Am J Perinatol 1999; 16:561.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/79\" class=\"nounderline abstract_t\">Mascaretti RS, Falc&atilde;o MC, Silva AM, et al. Characterization of newborns with nonimmune hydrops fetalis admitted to a neonatal intensive care unit. Rev Hosp Clin Fac Med Sao Paulo 2003; 58:125.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/80\" class=\"nounderline abstract_t\">Rose CH, Bofill JA, Le M, Martin RW. Non-immune hydrops fetalis: prenatal diagnosis and perinatal outcomes. J Miss State Med Assoc 2005; 46:99.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/81\" class=\"nounderline abstract_t\">Nakayama H, Kukita J, Hikino S, et al. Long-term outcome of 51 liveborn neonates with non-immune hydrops fetalis. Acta Paediatr 1999; 88:24.</a></li><li><a href=\"https://www.uptodate.com/contents/postnatal-care-of-hydrops-fetalis/abstract/82\" class=\"nounderline abstract_t\">Oudijk MA, Gooskens RH, Stoutenbeek P, et al. Neurological outcome of children who were treated for fetal tachycardia complicated by hydrops. Ultrasound Obstet Gynecol 2004; 24:154.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5027 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DIAGNOSIS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EPIDEMIOLOGY AND ETIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">PATHOGENESIS</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Elevated venous pressure</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Impaired lymphatic drainage</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Capillary oncotic pressure</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Hypoxia</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">MANAGEMENT</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Initial resuscitation</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Breathing</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Circulation</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">Assessment</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">- Examination of the infant and placenta</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Diagnostic evaluation</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">Further management</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">OUTCOME</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">Mortality</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Neurodevelopment outcome</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Recurrence</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/5027|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=OBGYN/70066\" class=\"graphic graphic_table\">- Causes nonimmune hydrops</a></li><li><a href=\"image.htm?imageKey=OBGYN/77350\" class=\"graphic graphic_table\">- Cardiac defects causing hydrops</a></li><li><a href=\"image.htm?imageKey=OBGYN/66844\" class=\"graphic graphic_table\">- Thoracic defects causing hydrops</a></li><li><a href=\"image.htm?imageKey=OBGYN/72575\" class=\"graphic graphic_table\">- Infections associated with nonimmune hydrops</a></li><li><a href=\"image.htm?imageKey=OBGYN/62279\" class=\"graphic graphic_table\">- Hematologic causes of fetal hydrops</a></li><li><a href=\"image.htm?imageKey=PEDS/57407\" class=\"graphic graphic_table\">- Metabolic causes hydrops</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-turner-syndrome\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Turner syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-cytogenetic-abnormalities\" class=\"medical medical_review\">Congenital cytogenetic abnormalities</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-myopathies\" class=\"medical medical_review\">Congenital myopathies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-hygroma-and-increased-nuchal-translucency\" class=\"medical medical_review\">Cystic hygroma and increased nuchal translucency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-initial-management-of-cyanotic-heart-disease-in-the-newborn\" class=\"medical medical_review\">Diagnosis and initial management of cyanotic heart disease in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=down-syndrome-clinical-features-and-diagnosis\" class=\"medical medical_review\">Down syndrome: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inborn-errors-of-metabolism-metabolic-emergencies\" class=\"medical medical_review\">Inborn errors of metabolism: Metabolic emergencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-pregnancy-complicated-by-rhesus-d-alloimmunization\" class=\"medical medical_review\">Management of pregnancy complicated by Rhesus (D) alloimmunization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-resuscitation-in-the-delivery-room\" class=\"medical medical_review\">Neonatal resuscitation in the delivery room</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nonimmune-hydrops-fetalis\" class=\"medical medical_review\">Nonimmune hydrops fetalis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-torch-infections\" class=\"medical medical_review\">Overview of TORCH infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hemolytic-anemias-in-children\" class=\"medical medical_review\">Overview of hemolytic anemias in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-alpha-thalassemia\" class=\"medical medical_review\">Pathophysiology of alpha thalassemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postnatal-diagnosis-and-management-of-hemolytic-disease-of-the-fetus-and-newborn\" class=\"medical medical_review\">Postnatal diagnosis and management of hemolytic disease of the fetus and newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-respiratory-distress-syndrome-in-preterm-infants\" class=\"medical medical_review\">Prevention and treatment of respiratory distress syndrome in preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-rhesus-d-alloimmunization-in-pregnancy\" class=\"medical medical_review\">Prevention of Rhesus (D) alloimmunization in pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-unconjugated-hyperbilirubinemia-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Treatment of unconjugated hyperbilirubinemia in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-chromosomal-microarray-in-obstetrics\" class=\"medical medical_review\">Use of chromosomal microarray in obstetrics</a></li></ul></div></div>","javascript":null}